|
 |
| EDITORIAL |
|
| Year : 2013 | Volume
: 61
| Issue : 9 | Page : 475-478 |
|
Anti-vascular endothelial growth factor in age-related macular degeneration: Puzzle or a silent beginning!
Sundaram Natarajan
Editor, Indian Journal of Ophthalmology, Chairman, Managing Director, Aditya Jyot Eye Hospital Pvt Ltd, Wadala (W), Mumbai, Maharashtra, India
| Date of Web Publication | 8-Oct-2013 |
Correspondence Address:
Sundaram Natarajan
Editor, Indian Journal of Ophthalmology, Chairman, Managing Director, Aditya Jyot Eye Hospital Pvt Ltd, Wadala (W), Mumbai, Maharashtra
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0301-4738.119421
How to cite this article:
Natarajan S. Anti-vascular endothelial growth factor in age-related macular degeneration: Puzzle or a silent beginning!. Indian J Ophthalmol 2013;61:475-8 |
Age-related macular degeneration is a leading cause of severe, irreversible vision impairment. [1] Elevated vascular endothelial growth factor (VEGF) levels significantly implicated in the pathogenesis of ocular neovascular diseases such as neovascular age-related macular degeneration (Wet-AMD). [2],[3] VEGF produced mainly by retinal pigment epithelium (RPE), pericytes, vascular endothelial cells, astrocytes, and muller cells is a pleuripotent growth factor that is essential for a variety of processes including maintenance of the adult microvasculature and trophic maintenance of ocular tissues. [4],[5],[6],[7],[8] VEGF-A has a potent effect on promoting endothelial cell proliferation and vascular permeability and is now established as the main factor for regulation of angiogenesis. [9],[10],[11] The VEGF 165 isoform induces angiogenesis and increases vascular permeability and inflammation and has been implicated in blood-retinal barrier breakdown and pathologic ocular neovascularization. [12] The currently employed three anti-VEGFs for the management of neovascular disorders of the eye have different isoform-binding properties. [13]
Pegaptanib sodium, an RNA aptamer, is a selective VEGF antagonist that binds to the 165 isoform of VEGF-A while sparing smaller isoforms. It was the first approved aptamer for therapeutic purposes paving the way for future applications. In December 2004, intravitreal injection of pegaptanib sodium was approved by the Food and Drug Administration (FDA) for the treatment of neovascular AMD including all subtypes with the dosage recommended as 0.3 mg every 6 weeks. Clinical trials have shown pegaptanib to be effective in cases of choroidal neovascularization secondary to AMD. [14],[15] Continuing visual benefit was observed in patients who were randomized to receive therapy with pegaptanib in the VISION trials when compared with 2 years usual care or cessation of therapy at year 1. [16] The VISION trial also demonstrated that pegaptanib used for wet AMD has a favorable safety profile, both ocular and systemic. [17]
Ranibizumab is a recombinant, humanized immunoglobulin G1 isotype that inhibits the biological activity of all isoforms of human VEGF-A. Four weekly intravitreal injection of ranibizumab 0.3 mg received approval of the FDA for the treatment of all subtypes of wet AMD in June 2006. [12] Before the FDA approval of ranibizumab 0.5 mg for patients with wet AMD, an open-label, uncontrolled, randomized clinical study demonstrated that doses of ranibizumab up to 2.0 mg were safe and well tolerated in this patient population. [18] More recently, the investigator-sponsored double dose (DoDo) trial demonstrated trends toward higher efficacy with less frequent injections using ranibizumab 1.0 mg compared with 0.5 mg for naive, wet AMD. Further study of higher dosing revealed favorable initial results when patients previously treated with ranibizumab 0.5 mg were switched to 2.0 mg in the investigator-sponsored super-dose anti-VEGF (SAVE) trial. [19] Initial trials have investigated on the dosage pattern of ranibizumab and have suggested use of 1.0 and 2.0 mg intravitreal dosage for wet AMD. [18],[19],[20] The EXCITE study demonstrated that after initial course of 3 monthly injections of intravitreal ranibizumab, both monthly (0.3 mg) and quarterly (0.3/0.5 mg) regimens show adequate efficacy. The trial did not record any noninferiority in regard to the quarterly regimen. [21] But the PIER study demonstrated that quarterly injections were inadequate and rolling over to monthly injections added benefit. The study also indicated individual variability to response and the need for tailored treatment. [22],[23] Pivotal studies like the SAILOR study, the ANCHOR trial, and the MARINA trial established the therapeutic advantages of intravitreal ranibizumab and led to the protocol of monthly intravitreal injections of 0.5 mg ranibizumab in neovascular AMD. [24],[25],[26],[27] The SUSTAIN study revealed that three initial monthly injections of ranibizumab provided preferable stability but subsequently, 9 months pro re nata (PRN) retreatment led to slight deterioration of visual acuity and OCT parameters. [28] The 12 and 24 months outcomes of the PRONTO study were similar to the phase 3 results of ANCHOR and MARINA, though dosage frequency was reduced. The study indicated that OCT would be an apt tool for decision making in regard to retreatment in wet AMD. [29] Monthly injection for 3 months followed by need-based injections (OCT-guided) on follow-up seemingly give a better result as compared with PRN protocol that starts with need-based injection in CNV secondary to AMD. [30] Higher evidence from ranibizumab trials suggests signals for an increased ocular and systemic vascular and hemorrhagic risk, which warrants further investigation. [31]
Bevacizumab is a monoclonal antibody approved by FDA to be used in metastatic tumors of breast, colon and nonsmall-cell lung cancer. Its effect on neovascular AMD was evaluated as an off-label drug, initially via intravenous route and then intravitreally in 2005. Both the routes demonstrated short-term efficacy. [32],[33],[34],[35] Bevacizumab therapy tried systemically (2-3 infusions) for wet AMD had shown to be well tolerated and effective in the subset of trial patients. Systemic therapy of avastin can be of aid in cases of exudative AMD where intravitreal injections cannot be given. [34],[35] Though larger clinical trials are required to establish its safety and efficacy profile, normal blood pressure and a negative history of thrombotic events are a prerequisite. [36] On evaluation of intravitreal therapy, in cases with subfoveal CNV, primary intravitreal bevacizumab (IVB) provides anatomic and functional stability and/or improvement demonstrable through OCT, fluorescein angiography (FA), and visual improvement. The outcomes are similar with dosage of 1.25 mg as is with 2.5 mg. [37] In patients with neovascular AMD, bevacizumab has shown to decrease macular thickness and improve visual acuity on 6 weekly dosage regimens or initial three doses at an interval of 6 weeks followed by 12 weekly schedule. [38] Short-term data of a study also suggests that 1.25 mg intravitreal dose of bevacizumab is well tolerated and translates to reduced macular thickness (OCT), reduced leakage (FA), and improved visual acuity even in cases of previous treatment with photodynamic therapy and/or pegaptanib. [39] Short-term trials also revealed promising functional and anatomic outcomes with IVB. The functional outcomes are known to depend not only on reduction of macular thickness but also on the treatment regimen. Studies also indicated that an OCT-guided regimen of intermittent retreatment is a novel approach. [40] The combination of IVB with low fluence PDT for the treatment of classic or predominantly classic neovascular AMD works in a synergistic fashion with a significant reduction in IVB reinjections rate. [41] Polypoidal choroidal vasculopathy with branching vascular networks respond well in terms of retinal morphology and visual stability over a year, though the response may reduce in due course. [42] The interpretation of the persistence of higher rates of serious adverse events with bevacizumab is uncertain. Acute intraocular inflammation may be associated with IVB and its differentiation from endophthalmitis is crucial to its management. [43],[44] The bevacizumab studies show too many methodological limitations to rule out any major safety concerns. [33]
Comparison of ranibizumab with bevacizumab demonstrated that both the drugs have equivalent effects on visual acuity. [45] Patients who continued treatment with either drug appeared to maintain benefits after 2 years. [46] Ranibizumab and bevacizumab had similar effects on visual acuity over a 2-year period. [43] Interim one year analysis of the IVAN trial reveals that both bevacizumab and ranibizumab have similar safety and efficacy profile in treatment of neovascular AMD. [47] It was also found that lesser than monthly regimens could achieve excellent results for both the drugs. But currently for bevacizumab, in contrast to ranibizumab, safety data are incomplete. [48] Recent data reveals that cases that do not respond sufficiently to anti-VEGF monotherapy show better results and reduced frequency of intervention when anti-VEGF is combined with PDT. [49]
Aflibercept is a soluble decoy receptor fusion protein. Intravitreal aflibercept injection (IAI) at doses of 0.5 and 2 mg provided the most robust outcomes in the Clinical Evaluation of Antiangiogenesis in the Retina Intravitreal Trial Phase 2 (CLEAR-IT 2). Aflibercept has shown to have a considerably greater binding affinity to VEGF when compared with bevacizumab or ranibizumab. This is postulated as being due to its possibly higher efficacy. [50],[51],[52],[53] Initial doses of three injections at monthly intervals when followed by injection every 2 or 3 months has been known to produce outcomes similar to monthly ranibizumab. A two monthly regimen possibly reduces the burden of monitoring monthly. [54] Converting patients of chronic neovascular AMD from bevacizumab and/or ranibizumab to aflflibercept results in stabilized vision and improved anatomic results, and also extends the intervals between injections. [55]
With increasing understanding of the molecular events cascading AMD is helping to bring stability in the battle against AMD, its pathogenesis still remains a jig-saw. Consequently the therapeutic armamentarium remains limited. Nevertheless, the burgeoning development of directed molecular interventions combined with the development of targeted delivery modalities offers hope in the battle against this blinding affliction.
| References | |  |
| 1. | Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, Huang SS, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration. A report by the American Academy of Ophthalmology. Ophthalmology 2008;115:1837-46.  |
| 2. | Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005;40:352-68. |
| 3. | Starita C, Patel M, Katz B, Adamis AP. Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (Macugen) in diabetic retinopathy. Dev Ophthalmol 2007;39:122-48. |
| 4. | Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011;56:95-113. |
| 5. | Adamis AP, Shima DT, Yeo KT, Yeo TK, Brown LF, Berse B, et al. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun 1993;193:631-8. |
| 6. | Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995;113:1538-44. |
| 7. | Bae JH, Lee SC. Bilateral intraocular inflammation after intravitreal bevacizumab in Behcet′s disease. Eye (Lond) 2010;24:735-45. |
| 8. | Famiglietti EV, Stopa EG, McGookin ED, Song P, LeBlanc V, Streeten BW. Immunocytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina. Brain Res 2003;969:195-204. |
| 9. | Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004;25:581-611. |
| 10. | Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9. |
| 11. | Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5. |
| 12. | Bhisitkul RB. Vascular endothelial growth factor biology: Clinical implications for ocular treatments. Br J Ophthalmol 2006;90:1542-7. |
| 13. | Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2009;20:158-65. |
| 14. | Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006;5:123-32. |
| 15. | Apte RS. Pegaptanib sodium for the treatment of age-related macular degeneration. Expert Opin Pharmacother 2008;9:499-508. |
| 16. | VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113:1508.e1-25. |
| 17. | Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E. et al. Pegaptanib sodium for neovascular age-related macular degeneration: Third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008;92:1606-11. |
| 18. | Brown DM, Chen E, Mariani AF, Major JC Jr, SAVE Study Group. Superdose Anti VEGF (SAVE) Trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular age-related macular degenerationprimary end point. Ophthalmology 2013;120:349-54. |
| 19. | Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006;113:623.e1 |
| 20. | Busbee B, Wu C, McCain M. Predictive factors for repeat dosing in wet AMD: Results from the DoDo trial. Presented at: The American Society of Retina Specialists 29 th Annual Meeting, Aug 20 -24, 2011. |
| 21. | Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: The EXCITE study. Ophthalmology 2011;118:831-9. |
| 22. | Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-48. |
| 23. | Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 2010;150:315-24.e1. |
| 24. | Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116:1731-9. |
| 25. | Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44. |
| 26. | Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.e5. |
| 27. | Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. |
| 28. | Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: The SUSTAIN study. Ophthalmology 2011;118:663-71. |
| 29. | Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: Year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.e1. |
| 30. | Arias L, Caminal JM, Casas L, Masuet C, Badia MB, Rubio M, et al. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 2008;92:1636-41. |
| 31. | Schmucker C, Loke YK, Ehlken C, Agostini HT, Hansen LL, Antes G, et al. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: A safety review. Br J Ophthalmol 2011;95:308-17. |
| 32. | U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Genentech, Inc. Avastin (Bevacizumab). Draft labeling text. BL125085/145 Amendment. Revised Feb 2008:13. Available from: http://www.fda.gov/cder/foi/label/2008/125085s1451bl.pdf . [Last accessed on 2008 Jul 7]. |
| 33. | Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-47. |
| 34. | Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006;113:2002.e1-12. |
| 35. | Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-5. |
| 36. | Schmid-Kubista KE, Krebs I, Gruenberger B, Zeiler F, Schueller J, Binder S. Systemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study. Br J Ophthalmol 2009;93:914-9. |
| 37. | Arevalo JF, Sánchez JG, Wu L, Berrocal MH, Alezzandrini AA, Restrepo N, et al. Intravitreal Bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at Twenty-four months: The Pan-American collaborative retina study. Ophthalmology 2010;117:1974-81. |
| 38. | Li X, Hu Y, Sun X, Zhang J, Zhang M; Neovascular Age-Related Macular Degeneration Treatment Trial Using Bevacizumab (NATTB). Bevacizumab for Neovascular Age-related Macular Degeneration in China. Ophthalmology 2012;119:2087-93. |
| 39. | Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72. |
| 40. | Weigert G, Michels S, Sacu S, Varga A, Prager F, Geitzenauer W, et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 2008;92:356-60. |
| 41. | Costagliola C, Romano MR, Rinaldi M, dell′Omo R, Chiosi F, Menzione M, et al. Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Br J Ophthalmol 2010;94:180-4. |
| 42. | Wakabayashi T, Gomi F, Sawa M, Tsujikawa M, Nishida K. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy. Br J Ophthalmol 2012;96:394-9. |
| 43. | Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology 2012;119:1388-98. |
| 44. | Wickremasinghe SS, Michalova K, Gilhotra J, Guymer RH, Harper CA, Wong TY, et al. Acute Intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2008;115:1911-5. |
| 45. | The CATT Research Group. Ranibizumab and bevacizumab for neovascular Age-Related macular degeneration. N Engl J Med 2011;364:1897-908. |
| 46. | Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: A systematic review and economic evaluation. Health Technol Assess 2008;12:iii-iv,ix-201. |
| 47. | The IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411. |
| 48. | Mitchell P. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Curr Med Res Opin 2011;27:1465-75. |
| 49. | Tozer K, Roller AB, Chong LP, Sadda S, Folk JC, Mahajan VB, et al. Combination Therapy For Neovascular Age-Related Macular Degeneration Refractory To Anti-Vascular Endothelial Growth Factor Agents. Ophthalmology 2013;pii:S0161-6420(13)00240-6. |
| 50. | Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 2003;9:47-52. |
| 51. | Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99:11393-8. |
| 52. | Heier JS, Boyer D, Nguyen QD, Marcus D, Roth DB, Yancopoulos G, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor Trap-Eye dosed as-needed after 12-week fixed dosing. Ophthalmology 2011;118:1098-106. |
| 53. | Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008;92:667-8. |
| 54. | Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-48. |
| 55. | Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eliott D, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol 2013;156:29-35. |
| This article has been cited by | | 1 |
Clinical translation of long-acting drug delivery formulations |
|
| Wei Li, Jie Tang, Dennis Lee, Thomas R. Tice, Steven P. Schwendeman, Mark R. Prausnitz | | Nature Reviews Materials. 2022; | | [Pubmed] | [DOI] | | | 2 |
Immune Inhibitor A Metalloproteases Contribute to Virulence in
Bacillus
Endophthalmitis
|
|
| Erin T. Livingston, Md Huzzatul Mursalin, Phillip S. Coburn, Roger Astley, Frederick C. Miller, Omar Amayem, Didier Lereclus, Michelle C. Callegan, Victor J. Torres | | Infection and Immunity. 2021; 89(10) | | [Pubmed] | [DOI] | |
|
 |
|
|
|
Search Pubmed for